Adolfo Garcia-Sastre, PhD
img_Adolfo Garcia-Sastre
DIRECTOR GLOBAL HEALTH AND EMERGING PATHOGENS INSTITUTE
PROFESSOR | Microbiology
PROFESSOR | Medicine, Infectious Diseases
PROFESSOR | Pathology, Molecular and Cell Based Medicine
Research Topics
Antivirals, Biodefense, Cellular Immunity, Cytokines, Gene Expressions, Gene Regulation, Gene Therapy, Immune Antagonism, Infectious Disease, Influenza Virus, Interferon, Interferon Antagonists, Interferon Resistance, Molecular Biology, Paramyxovirus, RNA, RNA Splicing & Processing, RNA Transport & Localization, Trafficking, Transcription Factors, Transcriptional Activation and Repression, Vaccine Development, Virulence Genes, Viruses and Virology
Multi-Disciplinary Training Area
Immunology [IMM], Microbiology [MIC]
The Garcia-Sastre Laboratory is focused on exploring virus-host interactions with an emphasis on virus regulation of innate and adaptive immune responses. The outcome of these interactions not only determines disease severity but also influences the development of protective immunity resulting from viral infection and/or vaccination. The team has developed several techniques (reverse genetics), which allow for the genetic manipulation of the genomes of several virus families including influenza virus and Newcastle disease virus. Other viruses being studied include Zika virus, Dengue virus, West Nile virus, and Crimean-Congo hemorrhagic fever virus. These techniques are currently being used in several research areas including: i) characterization of virus-encoded virulence factors, ii) identification of virus-encoded antagonists of the interferon system, iii) virus replication and gene expression, iv) immune regulation of influenza replication, and v) vaccine development. Reverse genetics are also being utilized to generate virus vectors based on influenza virus and Newcastle disease virus. These viruses are effective inducers of humoral and cellular immune responses. Live attenuated influenza virus vaccines are being generated by genetic modification of the influenza virus-encoded interferon antagonist that was originally identified by the laboratory. Also, recombinant viruses can be produced that express protective antigens of other pathogens for which no safe attenuated vaccine strains are available.

PhD, University of Salamanca

Publications

Selected Publications

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil. Érique José Farias Peixoto de Miranda, Rodrigo T. Calado, Fernanda Castro Boulos, José Alfredo de Sousa Moreira, Fabiane Fernandes Machado, Maria Aparecida Alves Leite Dos Santos Almeida, Marcia Cristina Oliveira Da Rocha, Vanessa Infante, Laina D. Mercer, Richard Hjorth, Rami Scharf, Jessica White, Christina Polyak, Rama Raghunandan, Adolfo García-Sastre, Weina Sun, Peter Palese, Florian Krammer, Bruce Innis, Cristiano Gonçalves Pereira, Esper Georges Kallas. Vaccine

Long-lasting B cell convergence to distinct broadly reactive epitopes following vaccination with chimeric influenza virus hemagglutinins. Jenna J. Guthmiller, Linda Yu-Ling Lan, Lei Li, Yanbin Fu, Sean A. Nelson, Carole Henry, Christopher T. Stamper, Henry A. Utset, Alec W. Freyn, Julianna Han, Olivia Stovicek, Jiaolong Wang, Nai Ying Zheng, Min Huang, Haley L. Dugan, Micah E. Tepora, Xueyong Zhu, Yao Qing Chen, Anna Karin E. Palm, Dustin G. Shaw, Madhumathi Loganathan, Benjamin F. Francis, Jiayi Sun, Jordan Chervin, Chloe Troxell, Philip Meade, Nancy H.L. Leung, Sophie A. Valkenburg, Sarah Cobey, Benjamin J. Cowling, Ian A. Wilson, Adolfo García-Sastre, Raffael Nachbagauer, Andrew B. Ward, Lynda Coughlan, Florian Krammer, Patrick C. Wilson. Immunity

Europe needs a sustainably funded influenza research and response network. Florian Krammer, Wendy S. Barclay, Martin Beer, Ian H. Brown, Rebecca Jane Cox, Menno D. de Jong, Ervin Fodor, Ron A.M. Fouchier, Gülsah Gabriel, Adolfo García-Sastre, Raquel Guiomar, Peter Horby, Marion Koopmans, Nicola S. Lewis, Stefania Maggi, Isabella Monne, Nadia Naffakh, Hanna Nohynek, Albert Osterhaus, Katarina Prosenc, Roman Prymula, Rino Rappuoli, Monika Redlberger-Fritz, Guus F. Rimmelzwaan, Colin A. Russell, Xavier Saelens, Martin Schwemmle, Derek J. Smith, Silke Stertz, Paula A. Tähtinen, Calogero Terregino, Charlotte Thålin. The Lancet Infectious Diseases

View All Publications

Adolfo Garcia-Sastre, PhD

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Garcia-Sastre during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Founder/Co-Founder/Partner

  • CastleVax Inc.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.